HRS2543 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Study of HRS2543 in Patients With Advanced Tumors (clinicaltrials.gov) - P1 | N=10 | Terminated | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | N=105 ➔ 10 | Trial completion date: Aug 2023 ➔ May 2024 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2023 ➔ May 2024; R&d strategy adjustment

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Oncology

A Study of HRS2543 in Patients With Advanced Tumors (clinicaltrials.gov) - P1 | N=105 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology